Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (1700)	8/29/2000 11:38:28 AM
From: Bill Tomko	Read Replies (1) \| Respond to of 2001

I spoke to GLIA IR and tried to get some clarification. ADCON-L was approved mostly upon European data and the interium US clinical studies with a promise to complete the clinical studies and submit a supplemental PMA. WHich was done in I beleive 1998. The FDA came in to audit the filing this June 2000. The 483 relates to the supplemental PMA filing. At no time did the FDA mention pulling the prodcut from the market. I INFERRED that the 483 MAY be JUST ONE of many reasons this merger was terminated. I strongly urged them to hold a CC at the ealiest possible time,explain the 483 and come clean on why the merger fell apart.